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MENGKAJI POTENSI ZARAH KANJI TEROPTIMUM SEBAGAI 
PELANTAR UNTUK PENYAMPAIAN ORAL SATU MODEL DRUG 
GASTROLABILE SEFOTAKSIM NATRIUM 
 
ABSTRAK 
 
 
Penggunaan zarah adalah pendekatan utama untuk sistem penghantaran kejuruteraan  
bagi mengatasi rintangan-rintangan di gastrousus. Kanji mempunyai ciri-ciri yang sesuai 
diperlukan sebagai satu zarah bahan pembuatan. Kanji mudah dibioteruraikan, selamat, 
murah dan banyak walaubagaimanapun, kurang digunakan sebagai bahan penyelidikan, 
berbanding biopolymer yang lain. Kerja ini melaporkan kaedah-kaedah yang mudah dan 
berinovasi termasuk pengeringan sembur, ultrasonikasi dan pengisaran nano untuk produksi 
saiz micron dan submicron zarah kanji. Zarah kanji teroptimum direka  melalui  kaedah 
pemprosesan dan formulasi menggunakan algoritma dengan bantuan komputer. 
 
Ultrasonifikasi gagal menghasilkan zarah kanji secara berulang dengan 
menggunakan bantuan pemprosesan. Pengeringan sembur menghasilkan partikel dengan saiz 
21.64 ± 1.36 µm (keseragaman 0.56 ± 0.135) bagi kanji jagung. Kaedah pengisaran nano 
kelihatan menjanjikan untuk penghasilan partikel submikron  secara berulang dengan 
kawalan mengenai ciri-ciri zarah  melalui modulasiparameter proses dan formulatif . Kanji 
kentang menghasilkan partikel bersilang dengan saiz dan indeks serakan berganda (PDI) 
masing-masing 200 nm dan 0.25. Potensi zeta untuk kanji kentang adalah > –21 mV. Kanji 
terlarutkan yang tidak bersilang menghasilkan partikel yang bersifat kation, anion dan 
neutral dengan potensi masing-masing +8.59 ± 0.45, –10.5 ± 0.20 dan 2.00 ± 0.30 mV, saiz 
partikel tersebut < 200 nm dan PDI < 0.25. Kanji jagung pula menghasilkan partikel tidak 
bersilang dengan saiz sekitar 500 nm dengan PDI > 0.40, iaitu satu nilai yang sedikit tinggi 
daripada nilai PDI yang boleh diterima, oleh itu partikel kanji jagung tidak dioptimakan. 
Persilangan kanji kentang dan jagung berciri hidrofobik.  
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Semburan kering kanji jagung, pengisaran nano silang- dan tidak bersilang kanji 
kentang dan beranion, kation dan neutral kanji terlarut dipilih untuk kajian in vitro dan in 
vivo. Kentang dan kanji terlarut menunjukkan keberkesanan muatan > 9.55%. Kanji jagung 
menunjukkan keberkesanan muatan yang rendah iaitu 2.30%, mungkin disebabkan hasil 
rendah kanji jagung (27.77 ± 1.48%) berbanding kanji kentang dan kanji jagung (> 84%). 
Pertumbuhan saiz zarah telah diperhatikan selepas tempoh waktu tertentu, dalam zarah kanji 
terlarut. Pembebasan in vitro zarah mematuhi model tertib sifar dengan eksponen resapan 
<1, menggambarkan sifat pembebasan oleh resapan bengkak. Perbandingan bagi sefotaksim 
natrium bebas, kanji kentang tidak bersilang dan kanji terlarut kation menunjukkan 4.82 dan 
2.59 lipatan peningkatan dalam ketersediaan biohayati, masing-masing. Oleh itu, kanji 
mungkin mempunyai potensi bagi menyampaikan gastrolabile drug, sefotaksim natrium dan 
dengan itu, untuk meningkatkan keterbiosediaan oral.  
 
Sebagai kesimpulan, partikel kanji bersaiz mikron dan submikron yang 
teroptimumkan boleh disediakan menggunakan kaedah fizikal melalui gabungan sains 
farmaseutikal dengan kaedah pengoptimuman dengan bantuan komputer. Zarah adalah 
mampu untuk meningkatkan keterbiosediaan sefotaksim natrium. Walaubagaimanapun, 
kestabilan fizikal zarah perlu terus untuk diperbaiki. 
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EXPLORING THE POTENTIAL OF OPTIMISED STARCH 
PARTICULATES AS PLATFORM FOR ORAL DELIVERY OF A MODEL 
GASTROLABILE DRUG CEFOTAXIME SODIUM 
 
ABSTRACT 
 
 
Use of particulates is a prominent approach for engineering delivery systems to 
overcome gastrointestinal barriers. Starch has desired properties necessary for a particulate 
fabrication material. It is biodegradable, safe, cheap and abundant however, has attracted less 
research attention, comparative to other biopolymers. This work reports simple and 
innovative top-down physical methods including spray-drying, ultrasonication and 
nanomilling for production of micron and submicron size starch particles. The optimised 
starch particulates were fabricated with use of processing and formulative aids employing 
computer-aided algorithm. 
 
Ultrasonication was unsuccessful in generating reproducible starch particles with 
processing aids used. Spray-drying produced particle size of 21.64 ± 1.36 µm (dispersion in 
uniformity of particle size 0.56 ± 0.135) for corn starch. Nanomilling seemed promising for 
production of reproducible submicron particles with control over particle characteristics by 
modulation of process and formulative parameters. Potato starch produced cross-linked 
particles with size and polydispersity (PDI) of 200 nm and 0.25, respectively. The zeta 
potential of potato starch was > –21 mV. Uncross-linked soluble starch yielded cationic, 
anionic and neutral particles with charges +8.59 ± 0.45, –10.50 ± 0.20 and 2.00 ± 0.30 mV, 
respectively with particle size < 200 nm and PDI < 0.25. Corn starch uncross-linked particle 
size was around 500 nm with PDI > 0.40 which was slightly higher than generally accepted 
PDI values, thus corn starch particles were not optimised. Cross-linked potato and corn 
starch were somewhat hydrophobic.  
 
The spray-dried corn starch, nanomilled cross- and uncross-linked potato starch and 
anionic, cationic and neutral soluble starch were selected for in vitro and in vivo studies. 
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Potato and soluble starch demonstrated loading efficiency > 9.55 %. Corn starch showed low 
loading efficiency of 2.30 %., probably due to its lower yield (27.77 ± 1.48 %) as compared 
to that of potato and corn starch (> 84 %). Particle size growth was observed over time 
prominently, in soluble starch particulates. The in vitro release of particulates followed zero 
order model with diffusion exponent < 1, characterising release by swelling-diffusion. 
Comparative to free cefotaxime sodium, the uncross-linked potato starch and cationic 
soluble starch showed 5.28 and 3.11 folds increase in bioavailability, respectively. Thus, 
starch may have potential to deliver gastrolabile drug, cefotaxime sodium and thereby, to 
enhance its oral bioavailability.  
 
In conclusion, the micron and submicron size optimised starch particles can be 
prepared using physical methods by blending pharmaceutical science with computer-aided 
optimisation. The particulates are capable to enhance bioavailability of cefotaxime sodium. 
However, physical stability of particulates is needed to be improved further. 
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CHAPTER 1 
GENERAL INTRODUCTION AND AIMS OF STUDY 
 
 
1.1 THE ORAL ROUTE OF ADMINISTRATION 
Among the routes of drug administration, per oral administration is the most 
dominant, convenient and preferred portal by which drugs are presented for systemic effects 
(Davenport, 1982; Lee and Yang, 2001). It is relatively safe and affords high acceptability, 
convenience and maximum compliance, in combination with the relative low cost, simple 
and cost-efficient manufacturing process (Lee and Yang, 2001). Nevertheless, the route is 
not without limitations, which prohibit the accomplishment of the full benefits of the route 
(Mahato et al., 2003). Substantial number of existing and new pharmaceuticals moieties 
exhibits poor oral absorption (Amidon et al., 1995; Hoerter and Dressman, 1997; Devane, 
1998). Despite of the above limitation, the design of an oral dosage form is usually the first 
choice for the new medicinal entities and aims to reformulate and/or optimise dosage forms 
of the existing drugs. The objective of the current oral formulation design is to develop a 
dosage form capable of absorption into blood in right time and amount after administration 
(Macheras et al., 1995). The drug absorption after oral administration is a complex process, 
requiring series of events (Ungell, 1997). 
 
1.1.1 Drug absorption after oral route of administration 
The small intestine usually is the most favourable site for drug absorption due to its 
large surface area endowed by microvilli and, therefore, delivery of drug to this region is 
usually a prerequisite for absorption (Davis et al., 1986). The microvilli consist of loose 
connective tissue and are supplied with blood and lymphatic system at their base (DeMarco 
and Levine, 1969). If absorbed into blood stream, the drug passes through the liver before its 
entry into the systemic circulation. However, the drug taken up by lymph accesses the 
systemic circulation without passing through liver (O’Driscoll, 1992; Ungell, 1997; Martinez 
and Amidon, 2002). Drug absorption after oral administration depends on physicochemical, 
pharmaceutical and physiological factors and on the efficiency with which a drug crosses the 
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several barriers prior to reaching into the systemic circulation (Kinget et al., 1998; Ashford, 
2002a; Ashford, 2002b; Mahato et al., 2003; Barrett, 2004). In line with the scope of the 
present study, only the physiological factors will be discussed under barriers to drug 
absorption after oral administration (Section 1.1.2). 
 
1.1.2 Barriers to drug absorption after oral administration 
GIT provides a variety of morphological (spatial) and physiological (functional) 
barriers to the arrival of a drug to systemic circulation (Ashford, 2002b). Morphological 
barriers are mucus and epithelial and endothelial cells while the physiological factors are pH, 
enzymes, presystemic biotransformation, enterohepatic circulation and counter absorption 
mechanisms (Shargel et al., 2004). The above barriers are given in Figure 1.1. 
 
Figure 1.1: Morphological and functional barriers for drug absorption after oral 
administration 
 
1.1.2(a) Gastrointestinal tract milieu 
The pH, enzymes, secretions and foods in gastrointestinal tract (GIT), together make 
the GIT milieu. The pH varies along the length of GIT, from very slightly acidic mouth 
region to very acidic region of stomach followed by another change to the neutral pH in the 
proximal small intestine (Davenport, 1982). Thus, the drug is exposed to fluctuating pH 
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while it passes along the GIT. The GIT pH influences or completely halts the absorption of 
drugs by affecting their chemical stability and ionisation or by acid- or base-mediated drug 
inactivation (Lee and Yang, 2001). Pepsin is the primary enzyme in the stomach while 
lipase, amylases and proteases are secreted from pancreas into the small intestine 
(Davenport, 1982). Drugs, particularly peptides, nucleotides and fatty acids are susceptible to 
enzymatic degradation (Lee, 1991; Wilson and Washington, 2001). The presence of food 
interferes with the drug absorption by retarding the gastric emptying time, provision of 
viscous environment and/or provoking the enzyme and acid secretions (Toothaker and 
Welling, 1980; Lee and Yang, 2001).  
 
1.1.2(b) Mucus 
Mucus on the lining of GIT epithelial cells is secreted by the mucosal cells of GIT 
epithelia. It consists of glycoprotein and glycocalyx (sulphated mucopolysaccharides) and is 
hydrophilic which is attributed to 95 % of water it contains (Csaky, 1984). Its most important 
property is the viscoelasticity, enabling it to act as a physical diffusion barrier for drug or to 
make complexes to some drugs thus, leading to impaired absorption (Gu et al., 1988; Norris 
et al., 1998; Ashford, 2002b). 
 
1.1.2(c) Epithelial cells – the mechanical barrier on the lumen side 
The small intestine is lined with a single layer of tightly joined columnar epithelial 
cells, called enterocytes (Squier, 1992; Lennernas, 1998). Higher molecular weight, lack of 
lipophilicity, presence of charge or epithelial binding prohibits translocation of certain drugs 
across intestinal epithelium (Gu et al., 1988; Tenhoor and Dressman, 1992; Squier, 1992; 
Amidon et al., 1995; Hoerter and Dressman, 1997). 
 
1.1.2(d) Epithelial permeation, transport pathways and mechanisms 
The uptake pathways, permeation mechanisms, transporters and efflux pumps have 
been regarded as biophysical and biochemical barriers. In the intestinal epithelium, the 
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possible mechanisms for the permeation of drugs are passive diffusion, carrier-mediated and 
endocytosis through the paracellular and transcellular pathways (Squier, 1992; Tsuji and 
Tamai, 1996). Paracellular drug flux is limited to small molecules and is of limited relevance 
in the most cases (Carino and Mathiowitz, 1999). The transcellular route is available for 
diffusion of small lipophilic molecules. The hydrophilic compounds are transported by 
carrier-mediated transport or by endocytosis (Carino and Mathiowitz, 1999; Ashford, 
2002b). 
 
In endocytosis, the particles are internalised by phagocytosis or pinocytosis and this 
occurs at specialised regions of membrane. Thus, drug absorption depends upon the region 
where they are present (Russell-Jones, 2004; Belting et al., 2005). After internalisation, the 
molecule may be acted upon by a range of destructive processes or substances including 
proteases and nucleases or is extruded out by efflux pumps. Distribution, affinity, capacity, 
specificity and direction of epithelial transporters and pumps play an important role in drug 
absorption (Ayrton and Morgan, 2001; Steffansen et al., 2004). Absorption of the following 
drugs is particularly affected; a) drugs having affinity to the intestinal transporters and b) 
drugs for which the passive diffusion is of no relevance due to higher molecular weight or 
low partition coefficient (Tsuji and Tamai, 1996; Ayrton and Morgan, 2001; Daniel, 2004; 
Steffansen et al., 2004). 
 
1.1.2(e) Efflux transporters and pumps 
The epithelial or endothelial permeability of a drug depends on the membrane 
carriers, known as “efflux transporters” which recognize substrate drugs and restrict their 
transport. The most documented efflux transporters belong to ATP-binding cassette, super 
family of transporters, including P-glycoprotein (P-gp) and multidrug resistance proteins 
(MRPs) (Kleinzeller, 1999; Westpahal et al., 2000; Walgren et al., 2000). The P-gp acts as a 
barrier by preventing drugs from crossing GIT epithelium into blood or extruding them from 
blood into bile. The transporters include a broad structural diversity of substrates and thus, 
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affect several therapeutic classes (Leonard et al., 2002; Chan et al., 2004). The MRPs confer 
resistance to substrate lipophilic anions. Many structurally diverse drugs are the substrates 
for MRPs (Borst et al., 1999; Bakos et al., 2000; Miller, 2001; Kim, 2003; Kruh and 
Belinsky, 2003). 
 
1.1.2(f) Endothelial cells – the mechanical barriers on apical side 
The endothelium, a cellular lining of the blood vessels underlying the GIT mucosa 
has fenestrations with pores of 80-100 nm size that allow paracellular transport. However, 
the presence of P-gp efflux in endothelium is highly restrictive for the transport of drugs 
using the transcellular route (Firth, 2002; Feng et al., 2002). 
 
1.1.2(g) Presystemic cellular metabolism 
The enterocytes contain phase I drug metabolizing enzymes, dominantly 
Cytochrome P450 (Wacher et al., 1996; Watkins, 1997) and hydrolytic and phase II drug 
metabolizing enzyme such as, acetyltransferases and sulfotransferases (Krishna and Klotz, 
1994; Wacher et al., 1998). The substrate drugs for the Cytochrome P450 (CYP450) enzyme 
undergo extensive metabolism after uptake in the intestinal wall (Kolars et al., 1991; Wacher 
et al., 1996; Benet et al., 1996; Wacher et al., 1998). The co-localisation of efflux 
transporters and metabolizing enzymes in the enterocytes, together with the substantial 
overlap in their substrate specificity, seems to indicate the existence of interplay between 
drug transporters and metabolizing enzymes suspected to synergize recycling of the substrate 
over the apical membrane. This increases the exposure of substrate drugs to the metabolizing 
enzymes (Cummins et al., 2002; Benet et al., 2004; Chan et al., 2004). 
 
1.1.2(h) Presystemic hepatic metabolism 
The heptoportal blood exposes the drugs to liver on its way to systemic circulation 
and the substrate drugs are extensively metabolised via oxidation by CYP450 enzyme or 
phase II reactions arising from conjugation with glutathione, sulphate or glucuronic acid. 
 6 
Only CYP3A4, a predominant member of the CYP450 mixed-function oxidase enzyme, 
metabolizes 50 % of all the drugs currently prescribed (Evans and Relling, 1999; Clarke and 
Jones, 2002). Thus, liver extraction and thereby premetabolism substantially reduces the 
systemic availability of susceptible drugs (Arimori and Nakano, 1998). 
 
1.1.2(i) Enterohepatic shunt 
The enterohepatic shunt is a cycle of events after drug absorption from intestine, 
where a drug secreted into the bile is presented to the intestine for absorption again and then 
secretion into bile. This cycle entails the increased persistence of drug in the body or 
inactivation of drug (Shargel et al., 2004). 
 
1.2 STRATEGIES TO OVERCOME BARRIERS FOR ORAL DELIVERY 
To be able to permeate through intestinal membrane, a drug must have following 
biopharmaceutical properties; ability to withstand the insults with appropriate stability in the 
hostile GIT environment, appropriate hydrophilicity to dissolve in the gastric fluids and 
sufficiently lipophilic to permeate through the cellular barrier (Thompson, 1997). 
Furthermore, it should not be a substrate for presystemic cellular or hepatic inactivation of 
efflux pumps (Ashford, 2002b). Several strategies have been proposed to generate or 
enhance the above biopharmaceutical features in the dosage form for oral delivery. Among 
many absorption barriers, the gastric liability has been addressed as one of the most 
important barriers in drug absorption (Amidon et al., 1995; Hoerter and Dressman, 1997; 
Macheras and Iliadis, 2005). In line with the scope of the present work, only the strategies to 
overcome insufficient gastric stability will be discussed. 
 
1.2.1 Approaches addressing gastric liability 
The drugs with adverse biopharmaceutical properties are usually delivered through 
parenteral route or are enteric-coated (Moes, 1993; Hillery et al., 2001). The parenteral route 
is invasive, usually with brief effects and impossible to terminate drug action, if required 
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(Robinson and Lee, 1987; Evers, 1997). The enteric coatings contain indigestible solids and 
make product often of considerable size, prohibitive for patients with gastric hypomotility or 
pyloric channel narrowing. The location where an enteric coating starts dissolving is 
uncertain and release may occur within the small intestine or deep in the colon. The large 
inter- and intra-patient variations leads to a varied drug release (Lee and Yang, 2001). To 
avoid the above limitations the recent research has been directed towards the use of 
convenient alternatives to parenteral route, such as sublingual, pulmonary and vaginal route 
for gastric liable drugs (MacGregor and Graziani, 1997) and preferably, to develop 
successful oral delivery systems (Lee, 1991; Zhou, 1994; Hillery et al., 2001). 
 
1.2.1(a) Chemical modification – prodrug and drug analogue 
A drug can be made enzymatically stable by presenting it as a prodrug with the 
substitution of chemical group(s) in the drug molecule (Vilhardt, 1990; Lloyd and Smith, 
1998). Recently PEGylisation, a chemical modification approach using conjugation or cross-
linking of drug with polyethylene glycol (PEG) has gained significant interest (Hinds, 2005). 
The approach prevents the degradation of PEGylised drug from proteolytic enzymes, reduces 
drug clearance rate and offers a shield to uptake by the reticuloendothelial system (RES) 
(Roberts et al., 2002). Nevertheless, prodrug strategy might not be adequate because a 
prodrug is considered as new chemical entity, thus requires the preclinical and clinical 
investigations. Therefore, approaches involving the change of formulation or engineering of 
the drug absorption are feasible (Hillery et al., 2001). 
 
1.2.1(b) Lipidisation strategies 
Lipidisation involves the formation of drug in appropriate pre-solubilised lipid 
phase, which by the metabolism of the lipids in GIT facilitates drug absorption 
(Humberstone and Charman, 1997). It may be achieved by incorporation of drug into lipid 
vehicle such as oils, surfactants, dispersions, micelles of mixed bile salt, liposomes, or 
emulsifying systems (Gershanik and Benita, 2000; Frokjaer et al., 2005). Such systems have 
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reported to improve bioavailability due to impeded gastric emptying time, increased 
permeability and facilitated lymphatic uptake mediated by special carriers, chylomicrons and 
very low density lipoproteins in epithelial cells (Sernka et al., 1979; Schilling and Mitra, 
1990; Macheras et al., 1995). 
 
1.2.1(c) Polymeric coating, encapsulation or entrapment 
Coating with, encapsulation and entrapment of drug in polymer is used to protect the 
gastric labile drugs. Depending upon polymeric materials used, they may form coating film, 
hydrogels and matrices (Grahan and McNeil, 1984; Kopecek et al., 1992; Brondsted and 
Kopeck, 1992). Several pH-dependent polymeric materials are available which are stable at 
acidic pH and dissolve in the intestinal or colonic pH. Thus, coating with such polymer 
protects the gastric unstable drugs (Touitou and Rubinstein, 1986; Saffran, 1991). Hydrogels 
are the cross-linked hydrophilic polymers able to swell in aqueous environment. This 
swellability is controllable by pH, degree of cross-linking and temperature. Hydrogels 
encapsulated drugs can be targeted to specific pH and thus, are attractive as drug delivery 
systems able to protect drugs at acidic pH (Frokjaer et al., 2005). 
 
1.2.1(d) Drug targeting to the lymphatics 
Oral route has proven feasible for the lymphatic uptake of lipophilic drugs and their 
subsequent access to the systemic circulation without passing through liver. The total flow 
rate of the lymph in the thoracic duct is approximately 100-200 ml/hr, 500 times less than the 
blood flow in portal vein (O’Driscoll, 1992; Porter and Charman, 2001). Thus, the lymph 
portal may be used to achieve sustained drug release and to avoid first pass metabolism. The 
endothelial layer of lymphatic capillaries is discontinuous or without basement membrane 
thus, allowing a free permeation, independent of the molecular size (Hastewell et al., 1991).  
 
A drug with molecular weight greater than 16,000 reaches systemic circulation 
through the lymph (Porter and Charman, 2001; Swartz, 2001; Feng et al., 2002). Delivery 
 9 
systems can selectively redirect drug absorption into the lymphatics. Drugs in lipid-based 
particles or oil enhances lymphatic uptake, while macromolecules and colloidal particles, 
after endocytosis or persorption (Figure 1.2) may enter the lymphatic system through clefts 
in the terminal vessels (Muranishi, 1997; Nishioka and Yoshino, 2001; Wassan, 2002). 
 
1.2.1(e) Drug targeting to the Peyer's patches 
Peyer's patches, concentrated in the ileum are the collection of large lymph tissues in 
the intestinal mucus-secreting lining and appear as the elongated thickened areas lacking villi 
(Figure 1.2). The patches are associated with the immune system and contain large number 
of lymphocytes. Specialised antigen-presenting epithelial cells, called modified epithelia (M) 
cells cover the patches. Features of M-cells, important in connection with drug absorption 
can be discriminated from that of the enterocytes. The M-cells have apical microfolds and 
lack or if have, under-developed microvilli and the mucus covering is assumed to be 
attenuated to allow antigenic uptake perhaps by adsorptive and/or receptor-mediated process. 
Thus, M-cells are capable of relatively extensive macromolecular endocytosis (Eldridge et 
al., 1990; Walgren et al., 2000). The phagocytotic potential of lymphocytes provides a 
concentration gradient for drug permeation. 
 
Figure 1.2: Microvilli showing epithelial cells and underneath two circulatory systems, blood 
and lymphatic stream. A special transport mechanism, persorption is also shown 
 10
Targeting the Peyer’s patches helps an enhanced drug uptake into lymphatics that 
depends on particles size, surface hydrophobicity and availability of specific targeting 
ligands (Eldridge et al., 1990; Muranishi and Yamamoto, 1994). Particle with size range of 
50-3,000 nm are taken up by the Peyer's patches and through the lymphatics, subsequently 
translocated to blood. The particles of size 0.5–1.0 µm are phagocytised by lymphocytes, 
which migrate to the draining lymph nodes (Jani et al., 1992; Randolph et al., 1999; Jung et 
al., 2000). The particles of size 3-10 µm are often retained within the Peyer's patches. 
Particles of size 2-3 µm exhibit the maximal phagocytosis (Champion et al., 2008). A higher 
uptake is generally observed for more hydrophobic microparticles. Monoclonal antibodies 
which bind to the specific M-cells-bound carbohydrate residues may increase 
microparticulates uptake (Eldridge et al., 1990). 
 
1.2.1(f) Targeted drug delivery to the colon 
A couple of strategies have been explored for targeting drug to the colon. One of the 
colonic drug delivery strategies is based on the design of a prodrug which is metabolised by 
enzymes found exclusively in the colon (Lee and Yang, 2001; Chourasia and Jain, 2003). 
Azoreduction of polymeric coating is a further important approach used for targeted drug 
delivery to the colon. The colonic anaerobic bacteria reductively cleave azo bonds leading to 
the disruption of the polymer network in the coating to release drugs (Van Den-Mooter et al., 
1992). Coating of azo polymeric systems onto pellets and solid unit dosage forms is another 
novel approach and shown to promote the oral administration of insulin and desmopressin 
(Saffran, 1991; Kopecek et al., 1992).  
 
Hydrogels are reported to have excellent persistence properties in the lower part of 
the rectum and hence demonstrate a potential of enhancing the colonic absorption of drugs 
(Grahan and McNeil, 1984; Brondsted and Kopecek 1992; Wilson et al., 1997). Dosage 
forms using pH-sensitive polymers and hydrogels have also been used for the drug targeting 
to desirable pH (Saffran et al., 1986; Chiu et al., 1999; Khan et al., 1999). Some other 
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approaches such as conjugation with glycoside, glucuronide, cyclodextrins, dextrans, amino 
acid and time-release system and bioadhesive systems have also been reported for the 
colonic drug delivery by Chourasia and Jain (2003). Impermeability of the colonic epithelia 
for drugs and long transit time of the colon are the major limitations for colonic drug 
delivery (Sangalli et al., 1999; Lee and Yang, 2001; Washington et al., 2001). 
 
1.2.1(g) General use of particulate drug carriers 
The colloidal particulates are becoming increasingly prominent in the novel drug 
delivery systems because of their potential for drug delivery, targeting, protecting gastric 
labile drugs and in parallel, protecting the GIT from drug toxicity and capacity for 
permeation into membranes (Ferrari, 2005). They are translocated in enterocytes, Peyer’s 
patches and M-cells simultaneously by para- and intra-cellular pathways and subsequently, 
gain access to lymphatics (Walgren et al., 2000; Feng et al., 2002). Several particulate 
carrier systems have been described including liposomes, nanoparticles, microparticles, 
microspheres, dendrimers and Ferro fluids (Artursson et al., 1984; Levy and Andry, 1990; 
Fournier et al., 1994; Jameela and Jayakrishnan, 1995). In accordance with the scope of the 
present study, the particulates will be emphasised more in Section 1.3. 
 
1.3 PARTICULATE DELIVERY SYSTEMS 
There is no agreed international definition of a nanoparticle, though Kreuter (1983a), 
Couvreur et al. (1986) and Allemann et al. (1993) have defined nanoparticles as the particles 
ranging in size from 10-1000 nm. A review of the internet (http://www.sciencedirect.com 
accessed on 27 May, 2006), revealed that the majority of the researchers are partial towards 
the above definition. However, according to the document PAS71 by Publicly Available 
Standard in collaboration with British Standards Institution, a nanoparticle is a particle 
having one or more dimensions of the order of 100 nm or less with the properties different 
from that of the bulk material (http://www.malvern.co.uk; accessed on 27 May, 2006). The 
nanoparticles are typically made of a single material in which a drug is entrapped, 
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encapsulated or adsorbed onto the surface (Kreuter, 1993; Kreuter, 1994). Generally, the 
spherical formulation with a particle size above 1 µm, with a distinguishable coating and 
core regions are referred to as microcapsules while matrix type structures are the 
microspheres or microparticles. Micelles are self-assembled block copolymers that form a 
hydrophilic layer and an inner hydrophobic core or vice versa. Dendrimers are 
monodispersed symmetric macromolecules with a large number of reactive end groups 
(Passirani and Benoit, 2005). The terms used to describe particulate carriers vary among the 
authors but herein the “particulate” will collectively be used for the systems of colloidal 
particulate intended for drug delivery. However, the references sustain the original 
terminology used by the authors. 
 
1.3.1 Liposomes 
Liposomes are microscopic vesicles composed of one or more lipid bilayers 
surrounding an aqueous space (Gregoriadis, 1991). Phospholipids are the most commonly 
used materials of fabrication for liposomes (Knight, 1981; Barratt, 2000). Both water and 
lipid soluble drugs can be entrapped within the aqueous compartment or lipid bilayers, 
respectively (Betageri el al., 1993a; Sharma and Sharma, 1997). Surface modification has 
improved the stability of liposomes in the gut and has facilitated permeation of drugs from 
gastrointestinal mucosa (Morgan and Williams 1980).  
 
Liposomes protect drug against enzymatic degradation and improve drug 
hydrophilicity (Al-Meshal et al., 1998; Bayomi et al., 1998; Weiner and Chiang, 1988; Kisel 
et al., 2001). Liposome-entrapped cefotaxime sodium has been reported to be a potential 
delivery system for oral route as indicated by its enhanced bioavailability (Betageri et al., 
1993b; Rojers and Habib, 1999; Ling et al., 2006). The phospholipids are readily hydrolysed 
or oxidised, thus liposomes require storage under nitrogen atmosphere. The liposomes are 
not compatible with several coatings of surfactants and are instable against the bile salts 
(Betageri et al., 1993c; Sharma and Sharma, 1997).  
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1.3.2 Solid lipid nanoparticles 
Solid lipid nanoparticles (SLNs) are the colloidal carrier for lipophilic drugs and 
composed of a high melting point lipid as a solid core coated with surfactants (Gassco, 1993; 
Muller et al., 1995; Chen et al., 2001). SLNs, the promising alternative delivery system to 
emulsions, liposomes and polymeric nanoparticles, can be administered through parenteral, 
oral or dermal route (Siekman and Westesen, 1992; Gassco, 1993) and share all the 
advantages of above in one carrier (Schwarz and Mehnert, 1999; Muller et al., 2000). 
 
1.4 GENERAL METHODS FOR PREPARATION OF PARTICULATES 
Nano- and microparticulates are formed by bottom-up or top-down procedures, the 
former procedure being used more frequently. In bottom-up procedure, the particulates are 
produced by polymerisation of monomers (dispersion polymerisation) or by shaping or 
condensation of macromolecules (coacervation, spray-drying, or solvent evaporation). 
 
1.4.1 Bottom-up procedures 
1.4.1(a) Emulsion/dispersion polymerisation 
In emulsion-polymerisation, particles are formed by chemically induced 
polymerisation of monomers dispersed in a continuous phase (Kreuter, 1983a). The 
polymerisation media may be aqueous or organic, employed for water-insoluble and soluble 
monomers, respectively (Gassco and Trotta, 1986; Krause et al., 1986). The polymer, on 
reaching certain molecular weight, form particles and becomes insoluble, leading to phase 
separation (Kreuter, 1982). The chemical initiator may be ammonium or potassium 
peroxodisulphate, bases or basic drugs (Kreuter, 1990; Kreuter 1992).  
 
The surfactants solubilise or disperse the insoluble monomers in continuous phase 
and stabilize the particulates while the cross-linker links the monomers (Schwarts and 
Rembaum, 1985). Emulsifiers are not mandatory for a hydrophilic macromolecule since it 
acts as dispersant (Kreuter, 1983a; Al-Khouri Fallouh et al., 1986). The drugs can either be 
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incorporated in particles during polymerisation process or adsorbed onto the formed 
nanoparticles (Allemann et al., 1993). The limitations of the applications are the conditions 
and solvents with respect to the stability of incorporated drug, drug-polymer reaction and the 
practically difficult removal of contaminants, un-reacted monomers or reaction initiator 
residues from the product (Fessi et al., 1989; Quintanar-Guerrero et al., 1996).  
 
1.4.1(b) Preparation from preformed polymers 
Use of the preformed and biodegradable macromolecules to prepare particulate 
carriers may prevent the problems associated with emulsion-polymerisation method. The 
principal methods for production of particulates from preformed polymers are 
emulsification-solvent evaporation, precipitation, or denaturation (Tice and Gilley, 1985; 
Fessi et al., 1989). Solvent evaporation is usually referred to as the phase separation when a 
water insoluble polymer is in question, while the term coacervation is used for separation of 
water-soluble macromolecules (Fessi et al., 1989; Jeffery et al., 1991; Jeffery et al., 1993). 
 
I Emulsification-solvent evaporation 
In the emulsification-solvent evaporation, a polymer dissolved in a water-immiscible 
volatile organic solvent is emulsified in the aqueous medium to form oil-in-water emulsion. 
The subsequent evaporation of the organic solvent, by heating or reduced pressure solidifies 
the organic phase droplets to particles. Drug is incorporated during the production as 
dissolved or suspended in the polymer solution in the organic solvent (Tice and Gilley, 1985; 
Al-Khouri Fallouh, 1986). The final product may require centrifugation, washing and 
lyophilisation (Krause et al., 1985; Jeffery et al., 1991).  
 
Double emulsion solvent-evaporation, a modification of the emulsification solvent 
technique improves the loading efficiency of hydrophilic drugs but yields relatively larger 
particle size. In this approach, an aqueous drug solution is first emulsified in an organic 
solution of polymer to yield primary emulsion, which then is poured to the larger volume of 
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aqueous phase (Blanco-Prieto et al., 1994; Rafati et al., 1997; Delie et al., 2001). Limitations 
of the method are the same as those mentioned for emulsion polymerisation (Verrecchia et 
al., 1995). 
 
II Coacervation (phase separation) method 
Coacervation involves a separation of a polymer from its solution and deposition 
around a drug to be coated. In this process, a synthetic polymer is dissolved in a water-
immiscible organic solvent and the separation is induced by the addition of another organic 
solvent or oil (Ruiz et al., 1989; Sampath et al., 1992). The polymer may also be dissolved in 
a water miscible solvent and then poured into a non-solvent (usually water with surfactant). 
The polymer separation is also induced by a change of surface charge by ionic gelation, 
temperature, or pH and addition of salt (salting out) or incompatible polymer (Calvo et al., 
1997). Addition of desolvating agents causing the so-called salting out phenomenon can also 
be used to form coacervate. The organic solvent is evaporated under a reduced pressure 
(Oppenhiem et al., 1984). Hardening is achieved by addition of a cross-linker, thus, 
purification from hardening agent is a disadvantage of this method (Fessi et al., 1989). 
Recently, a complex coacervation or polyelectrostatic complexation method has been 
reported for the preparation of nanoparticles in which the polymer-polymer or polymer-drug 
complex is formed by electrostatic interactions (Liu et al., 2007; Bayat et al., 2008a; Bayat et 
al., 2008b). 
 
1.4.1(c) Solvent deposition/displacement (nanoprecipitation) 
Nanoprecipitation is a simple, one-step and straightforward technique for 
preparation of nanoparticles. It is carried out with two miscible solvents, the first one must 
be the solvent ideally for both polymer and drug while the second is a non-solvent for both. 
Addition of polymer solution to the non-solvent leads to nanoprecipitation by a rapid 
diffusion of polymer-containing solvent into the dispersing medium (also called desolvation 
of polymer). The drug is encapsulated in the polymer (Fessi et al., 1989; Bilati et al., 2005). 
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1.4.1(d) Emulsification-cross-linking 
In this method, the aqueous solutions of polymer and of the drug to be incorporated 
into the particles are emulsified in oil, which result in the formation of droplets. The droplets 
can then be hardened by addition of cross-linkers or by denaturation of the molecules at high 
temperatures (Gupta el al., 1986; Kreuter, 1992). The addition of surfactants stabilizes the 
emulsion and helps re-suspension of the final dry nanoparticles in water (Widder et al., 
1979; Gupta et al., 1986). 
 
1.4.1(e) Desolvation of macromolecules 
Particles can be produced after dissolution of relatively hydrophilic copolymers or 
macromolecules in water-miscible solvents. The solutions of the polymer and of the drug to 
be entrapped in the above solvents are then poured into water, resulting in the spontaneous 
formation of particles due to desolvation. The particles produced by this method however, 
are not redispersible in water after spray- or freeze-drying (Bodmeir et al., 1991). Addition 
of desolvating agents results in precipitation of macromolecules or coacervation as a new 
phase. The polymer may be gelatine, human serum albumin, bovine serum albumin, casein 
and ethyl cellulose. In some cases, surfactants are required in order to solubilise certain 
drugs or to facilitate the redispersion of the final freeze-dried product (Marty et al., 1978).  
 
1.4.2 Supercritical fluid technology 
Use of organic solvents/or some chemical reaction stabilizing the colloid structure 
and thus, the need of extensive purification can be avoided by use of supercritical fluid 
technology. The supercritical fluid technology yields organic solvent-free and pure particles 
thus, is highly environment-friendly. In this technology, the solution of material of interest in 
a supercritical fluid is expanded through a nozzle. An abrupt decrease in the solvent power 
on expansion results in precipitation of solute (Tom and Debenedetti, 1991). Nevertheless, 
insolubility of polymers (MW >10,000 D) in supercritical fluid had made this technique 
impractical (Tom et al., 1994). 
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1.4.3 Top-down procedure 
Top-down procedures employ the physical energy or stress to reduce the particle 
size of a coarse polymer. Extrusion and wet-grinding (nanomilling) are the two common 
physical methods and require the coarse polymer to be grinded in a dispersion medium 
containing surfactants, stabilizers and other adjunctive materials. Size reduction is achieved 
by shearing forces (tearing apart), influencing forces (crushing and impinging) and attrition 
(tearing-impacting combined) (Yilmaz et al., 2001). 
 
1.4.3(a) Extrusion 
Extrusion is employed by an instrument, called extruder that has two counter 
rotating screws through which the material is passed to reduce the size (Patent No WO 
00/40617, 2000). Extrusion is cost effective, environment-friendly technology and thus, is an 
attractive method to encapsulate a great variety of bioactive substances in starch matrices. 
Yilmaz et al. (2001) has comprehensively reviewed the use of extrusion for this purpose. 
Perhaps, use of a higher volume is a dominating reason for its limited use in the current 
research.  
 
1.4.3(b) Wet-grinding (nanomilling) 
Wet-grinding or nanomilling, using media-mills requires small volume, this coupled 
with efficiency in reducing the particle size and use of wet-grinding is gaining attraction in 
size reduction. So far, application of the wet-grinding has been confined only to the material 
research and there are a few reports on its use for pharmaceutically applicable nanomaterials 
(Merisko-Liversidge et al., 1996; Merisko-Liversidge et al., 2003). 
 
1.4.4 Materials of fabrication of particulates 
Natural polymeric materials or their derivatives such as dextran, maltodextrin, 
mannan, or other starch derivatives, albumin and gelatine have been studied for developing 
particulate delivery systems (Schroder et al., 1985; Artursson et al., 1987; Artursson et al., 
 18
1988; Fahlvik et al., 1990). However, the synthetic polymeric materials are usually preferred 
due to their consistent properties, biodegradability, biocompatibility and compatibility with 
drugs. Copolymers such as poly (lactic-co-glycolic acid) or poly(lactic acid)-polyethylene 
oxide, have been well-documented (Vert, 1986; Kissel and Koneberg, 1996). Majeti and 
Kumar (2000) reviewed materials currently used in preparation of particulate materials. 
Some of the synthetic materials are costly while others have some degree of toxicity 
(Kreuter, 1992; Kreuter, 1993; Kreuter, 1994). Several features of starch, stated in Section 
1.6.4 have motivated the use of starch as the fabrication material.  
 
1.5 GENERAL APPLICATIONS OF PARTICULATES 
1.5.1 Oral delivery of peptides, gastrolabile drugs and vaccines 
Presenting the gastric instable drugs in particulates offers gastric stability, improves 
cellular uptake and due to their access to lymphatics, avoids first pass effects (Gautier et al., 
1992; Bayat et al., 2008a Bayat et al., 2008b). Particulate-bound gastric labile and water 
insoluble drugs exhibit enhanced bioavailability (Eldridge et al., 1990; Jani et al., 1992). 
Recently, Pereira (2008) demonstrated an enhanced absorption of Eudragit-loaded 
cefotaxime sodium in rats. A drug in nanoparticles may have a long-term effect due, in part 
to the formation of a depot in the gut wall, Peyer's patches, lymphatic system and/or other 
body compartments (Grangier et al., 1991). 
 
1.5.2 Targeting infected and inflamed cell 
The nanoparticles are readily taken up by phagocytic cells, Kupffer cells and 
monocytes (Lam and Mathison, 1982), making targeting possible for nanoparticle-bound 
drug to these cells and the alveoli with an improved drug efficacy (Eltahawy, 1983). The 
infected reticuloendothelial system (RES) cells with human immunodeficiency virus or 
leishmaniasis and inflamed cells show preferentially higher phagocytosis of nanoparticles-
bound drugs (Mizushima, 1985; Fouarge et al., 1989; Meltzer et al., 1990; Losa et al., 1991).  
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1.5.3 Targeting cytostatics to tumours 
The particulates accumulate in a number of tumours, may be due to their increased 
bioadhesiveness towards the tumours (Gipps et al., 1986; Alpar et al., 1989; Illum et al., 
1989). It may also be attributed to endocytosis of particles by endothelial cells lining the 
tumour vasculature or escape of particles through leaky or open blood vessels (Couvreur et 
al., 1982; Widder et al., 1983; Gupta et al., 1989). Nanoparticles have prolonged persistence 
time in a variety of tumours and metastases with enhanced efficacy and decreased toxicity of 
a number of cytostatics (Brasseur et al., 1980; Couvreur et al., 1986; Ferrari, 2005). 
 
1.5.4 Ophthalmic delivery 
Ocular drug in a particulate delivery system increases the residence time of drug as 
compared to the conventional ocular delivery systems that have fast washout due to rapid 
tear turnover, lachrymal drainage and dilution of tears (Lee and Robinson, 1979; Losa et al., 
1993; Zimmer et al., 1995). The persistence time of drug can be further enhanced by using a 
strong bioadhesive substance for nanoparticle fabrication (Gurny et al., 1987). 
 
1.5.5 Vaginal drug delivery 
Microparticulate systems have been investigated for drug and vaccine delivery 
through vaginal mucosa (Okada, 1991; Hagan et al., 1993). Starch microspheres, 40 µm in 
diameter, were shown to be capable of enhancing the vaginal absorption of insulin (Okada, 
1991). 
 
1.5.6 Enhancing drug safety 
Due to the selective localisation in the infected cell and tumours, the particulate drug 
delivery systems reduce drug delivery to the non-targeted tissues (Lam and Mathison, 1982; 
Eltahawy, 1983). Thus, such systems have potentials to improve efficacy, safety and reduce 
the chances of drug resistance (Fouarge et al., 1989; Schafer et al., 1992). 
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1.5.7 Adjuvants for vaccines 
Nano- and microparticles claim most of the desired features that the vaccine carriers 
must have (Wikingsson and Sjoholm, 2002), thus are promising for use as adjuvant for 
vaccines (Chen et al., 1998; Singh et al., 2000; Briones et al., 2001). Their slow degradation 
offers long persistence in body, prolonged contact of antigen with immunocompetent cells 
and thus able to maintain a long immunity (Kreuter et al., 1986; Hedley et al., 1999; 
Herrman et al., 1999; Cui and Mumper, 2003). 
 
1.6 STARCH AS THE MATERIAL OF PARTICULATE FABRICATION 
Starch, the material of fabrication for particulate carrier in this study is the major 
carbohydrate reserve in plant. It is a semi-crystalline material extracted from a variety of 
sources, maize being the predominant followed by wheat potato and rice barley (Buléon et 
al., 1998; De-Baere, 1999; Gordon, 1999; Wesslén and Wesslén, 2002). Chemically, starch 
is a polysaccharide that consists of repeating glucose units (Li and Yeh, 2001; Singh et al., 
2003). Starch is abundantly available, cheap and is widely used polymer. The properties of 
native starch, being dependent upon the source are inconsistent but the commercially 
available starch is with consistently uniform quality (Gordon, 1999) as freely flowing white 
coloured powder.  
 
Starch has found diverse and wide range of applications in pharmaceutical and non-
pharmaceutical fields. It is used as staple food, raw material (Aime et al., 2001), source of 
energy (calories), thickener, gelling agent (Aime et al., 2001; Tester and Karkalas, 2002) and 
as a dietary fibre (www.Isbu.ac.uk/water/hysta.html; Accessed on 7 December, 2005). In 
pharmaceutical field, starch is used conventionally as a thickener, tablet binder, diluent, 
disintegrant, stabilizer, gelling agent and as a drug carrier. In topical preparations, it is used 
as dusting-powder for its absorbency , as a protective covering in ointment formulations and 
as an emollient (Bayazeed et al., 1989; Whaley et al., 1999; Schmidt et al., 2001; Jeffcoat et 
al., 2002; Lind et al., 2002). 
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1.6.1 Starch composition and molecular structure 
Though varied in structure and composition, each starch granule primarily contains 
blends of two polyglucans, amylose and amylopectin, both being associated through 
hydrogen bonding and arranged in layers to form granules (Hovenkamp-Hermelink et al., 
1987; Tomlinson et al., 1997; Li and Yeh, 2001; Vorwerg et al., 2002). 
 
1.6.1(a) Amylose 
Amylose is mostly linear fraction consisting of about 500 – 20000 α-D-glucose units 
linked through α (1→ 4) linkage and accounting for 20-30 % of the total starch (Li and Yeh, 
2001). It has lower molecular weight (105–106 g/mol) but has a relatively extended shape 
with radius of 7-22 nm and generally tends to wind up into single or double helical junction 
zones. Hydrogen bonding is also present between the aligned chains (Morrison et al., 1986; 
Morrison et al., 1993a; Hoover, 2001). 
 
1.6.1(b) Amylopectin 
Amylopectins are branched fractions containing short chains linking linear chains 
via α (1→ 6) linkages, forming branching point at one residue in every twenty and some 
cases, every thirty residues, thus making it a huge but compact molecule with molecular 
weights between 106 and 107 g/mol (Hoover, 2001; Li and Yeh, 2001). Each amylopectin 
molecule contains up to two million glucose residues and has a hydrodynamic radius of 21-
75 nm (Parker and Ring, 2001). It accounts for 70-80 % of total starch. Hydrogen bonding 
between sequential residues encourages a helical conformation in amylopectin (French et al., 
1984; Li and Yeh, 2001; Parker and Ring, 2001). 
 
1.6.1(c) Molecular arrangement of amylose and amylopectin 
Amylose and amylopectin molecules are oriented as alternating semi-crystalline 
(dark) and amorphous layers, forming concentric regions in granules. In semi-crystalline 
layer, the ordered regions compose of double helices of short amylopectin branches. The 
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amorphous regions of the semi-crystalline layers and the amorphous layers are composed of 
amylose and non-ordered amylopectin branches (Yamaguchi et al., 1979; Jenkins et al., 
1993; Donald et al., 1997; Gallant et al., 1997; Baldwin et al., 1998; Baker et al., 2001; 
Parker and Ring, 2001). 
 
1.6.1(d) Other minor components 
Starch may have some minor components such as lipids, fatty acids, phosphorus and 
proteins (Morrison, 1993a; Lim et al., 1994; Hizukuri et al., 1996; Jane et al., 1996; Ellis et 
al., 1998; Tester and Karkalas, 2002). 
 
1.6.2 Types of starches 
Based on source, the starches are grouped as corn (maize), potato, rice, tapioca and 
wheat. Depending on contents, starches are waxy when the amylose to amylopectin ratio is 
low (≈ 15 %), normal when amylose represents ≈ 16-35 % and high-amylose when amylose 
content exceed ≈36 % (Morrison, 1993b). The common corn starch has 25 % amylose while 
the waxy corn starch is almost totally made up of amylopectin. The granules of high-amylose 
starch tend to be smooth and have a narrower size range. Potato starch has about 20 % of 
amylose (Jane et al., 1994). 
 
1.6.2(a) Modified starches 
Starch is modified to enhance and expand its functionality and is achieved 
chemically, enzymatically, physically, or by biotechnological approach due to rupture of all 
or part of starch granules (Jobling, 2004). Physical modification can be achieved by milling 
to produce damaged starch granules. Pregelatinised starch is obtained using a physical 
method by the simultaneous gelatinisation and drying of aqueous starch dispersions. In this 
process, heating of starch in excess water induces many physical changes such as loss of 
crystallinity, swelling and rupturing of starch granules (Blanshard, 1987; Tester, 1997). 
Gelatinised starch is easily dispersed in cold water. Extrusion of starch is another physical 
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method (Giezen et al., 2004). Other methods include enzymatic modification by α- β-
amylase and amyloglucosidase are used to hydrolyse starch. The cross-linked starches are 
produced by chemical modification (Tester and Karkallas, 2002). 
 
1.6.3 Functionality of starch 
1.6.3(a) Gelatinisation 
On heating starch in excess water, starch granules absorb water and while hydrogen 
bonding between amylose and amylopectin maintains granule integrity, it begins to swell 
from hilum (centre). Granules lose organised structure, crystallinity and become amorphous. 
Ultimately, granule structure is completely lost resulting into a thin paste (<4 %) or gel (>4 
%). Typically, this process begins at 45°C, peaks at 60°C and completes at 75°C. 
Gelatinisation renders starch easy deformation and complete digestibility. Degree of swelling 
dictates the extent of starch water binding capacity (Jane et al., 1996; Li and Yeh, 2001; 
Rosa, 2004; Tester et al., 2004). After gelatinisation starch, which is otherwise water 
insoluble, becomes water soluble (Dziechciarek et al., 1998; Jane et al., 1999; Tester and 
Sommervillie, 2003). The common solvents for starch are sodium or potassium hydroxide 
and dimethyl sulfoxide (Radosta et al., 2001). Higher amylose content, owing to the 
extensive hydrogen bonding, requires more energy to gelatinise the starch. Thus, high 
amylose starch have less swelling power and higher gelatinisation temperatures (Li and Yeh, 
2001; Singh et al., 2003). The presence of phosphate groups in starch increases its swelling 
power. Certain salts such as calcium chloride and lithium chloride promote gelatinisation of 
starch at room temperature (Jane, 1994; Jane et al., 1999; Pan and Jane, 2000). 
 
1.6.3(b) Hydrocolloidal functionality 
Starch functions as hydrocolloid due to the presence of amylose and amylopectin. 
The extended and loose helical amylose chains have a relatively hydrophobic inner surface. 
Similarly, helical structure in amylopectin may present continuous hydrophobic surface 
(King, 1995; Whaley, 1999). 
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1.6.3(c) Thickening agent 
Viscosity is purely a function of molecular weight of substances. The branched 
structure of amylopectin with all attached chains yields much larger molecule than amylose. 
Consequently, it builds higher viscosity thus the waxy starches have higher viscosity. 
Amylopectin interferes with the interaction between amylose chains and its solution that can 
lead to an initial loss in viscosity followed by a more slimy consistency. After gelatinised, 
the swollen granules increase the viscosity of dispersion (Bayazeed et al., 1989). 
 
1.6.3(d) Gel and film formation 
In a solution, amylose molecules easily align themselves with one another and 
associate through hydrogen bonding to form gels or films. This property is useful for several 
applications such as coating and for the inclusion of fats and flavours in starch (Shinsato et 
al., 1999). In general, higher degree of polymerisation (length of amylose in starch) gives 
greater gel strength due to its increased ability to associate through hydrogen bonding. High 
amylose starches show better film forming properties. Gelatinisation creates more tendencies 
for association of granules to form gels and films (Roper and Koch, 1990; Zeller et al., 1999; 
Haugaard et al., 2001). 
 
1.6.3(e) Retrogradation 
Tendency of re-association of the gelatinised starch molecules with one another on 
cooling and thereby, forcing water out of the molecule, causing starch to recrystallise is 
called retrogradation. This unique property of starch is due to the presence of amylose. 
Branched amylopectin impedes retrogradation but the long branched amylopectin are 
susceptible to retrogradation. Mixing with carrageenan, alginate and xanthan gum and low 
molecular weight sugars can reduce retrogradation. On release of water, the aligned chains 
may form double stranded crystallites that are resistant to amylase and due to extensive inter- 
and intra-strand hydrogen bonding makes hydrophobic structure of low solubility (Shogren 
et al., 1992; www.lsbu.ac.uk/water/hysta.html: Accessed on 7 December, 2005). 
